NASDAQ:LNTH Lantheus - LNTH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $81.76 -1.10 (-1.33%) (As of 03/22/2023 03:25 PM ET) Add Compare Share Share Today's Range$81.36▼$83.5450-Day Range$50.04▼$82.8652-Week Range$47.46▼$87.47Volume669,064 shsAverage Volume1.03 million shsMarket Capitalization$5.52 billionP/E Ratio240.47Dividend YieldN/APrice Target$107.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Lantheus MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside30.1% Upside$107.33 Price TargetShort InterestBearish5.63% of Float Sold ShortDividend StrengthN/ASustainability-1.67Upright™ Environmental ScoreNews Sentiment0.39Based on 10 Articles This WeekInsider TradingSelling Shares$11.50 M Sold Last QuarterProj. Earnings Growth17.71%From $4.46 to $5.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.59 out of 5 starsMedical Sector101st out of 983 stocksDiagnostic Substances Industry1st out of 14 stocks 3.5 Analyst's Opinion Consensus RatingLantheus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $107.33, Lantheus has a forecasted upside of 30.1% from its current price of $82.47.Amount of Analyst CoverageLantheus has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.63% of the float of Lantheus has been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lantheus has recently increased by 32.86%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLantheus has received a 61.07% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Diagnostic radiopharmaceuticals", and "Therapeutic radiopharmaceuticals" products. See details.Environmental SustainabilityThe Environmental Impact score for Lantheus is -1.67. Previous Next 3.0 News and Social Media Coverage News SentimentLantheus has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Lantheus this week, compared to 5 articles on an average week.Search Interest59 people have searched for LNTH on MarketBeat in the last 30 days. This is an increase of 136% compared to the previous 30 days.MarketBeat Follows10 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,503,130.00 in company stock.Percentage Held by InsidersOnly 1.60% of the stock of Lantheus is held by insiders.Percentage Held by Institutions97.62% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Lantheus are expected to grow by 17.71% in the coming year, from $4.46 to $5.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 242.56, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 118.83.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 242.56, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 89.21.Price to Book Value per Share RatioLantheus has a P/B Ratio of 12.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lantheus (NASDAQ:LNTH) StockLantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in Bedford, MA.Read More Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address LNTH Stock News HeadlinesMarch 10, 2023 | marketbeat.comAre These Medical Device Makers Getting Ready To Rally? (LNTH)Current trends and changing demographics are behind growth of medical technology companies. An aging population and a shift to in-home care are among factors.March 22, 2023 | finance.yahoo.comRecent Price Trend in Lantheus Holdings (LNTH) is Your Friend, Here's WhyMarch 22, 2023 | Investing Daily (Ad)This Trade Strategy Outpaces Almost AnythingDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. March 20, 2023 | finance.yahoo.comDoes This Valuation Of Lantheus Holdings, Inc. (NASDAQ:LNTH) Imply Investors Are Overpaying?March 20, 2023 | americanbankingnews.comInsider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Sells $27,629.88 in StockMarch 17, 2023 | finance.yahoo.comHas Cardiff Oncology (CRDF) Outpaced Other Medical Stocks This Year?March 17, 2023 | finance.yahoo.comDoes Lantheus Holdings (LNTH) Have the Potential to Rally 32.44% as Wall Street Analysts Expect?March 17, 2023 | finance.yahoo.comLantheus Announces Two Key Executive PromotionsMarch 22, 2023 | Investing Daily (Ad)How This Trader Banked A 97% Win RateDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. March 16, 2023 | finance.yahoo.comIBD Stock Of The Day Lantheus Continues Its Run With A BreakoutMarch 14, 2023 | americanbankingnews.comLantheus Holdings, Inc. (NASDAQ:LNTH) Receives $108.25 Average Target Price from AnalystsMarch 13, 2023 | finance.yahoo.comZacks.com featured highlights include Encore Wire, ICF International, Lantheus Holdings and TecnoglassMarch 13, 2023 | americanbankingnews.comLantheus Holdings, Inc. (NASDAQ:LNTH) CEO Sells $751,780.80 in StockMarch 10, 2023 | finance.yahoo.comHere is Why Growth Investors Should Buy Lantheus Holdings (LNTH) NowMarch 2, 2023 | finance.yahoo.comBull of the Day: Lantheus (LNTH)March 1, 2023 | finance.yahoo.comIs Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?March 1, 2023 | finance.yahoo.comWall Street Analysts Predict a 41.16% Upside in Lantheus Holdings (LNTH): Here's What You Should KnowFebruary 26, 2023 | finance.yahoo.comNews Flash: Analysts Just Made A Captivating Upgrade To Their Lantheus Holdings, Inc. (NASDAQ:LNTH) ForecastsFebruary 25, 2023 | finance.yahoo.comWhy Shares of Lantheus Holdings Rose This WeekFebruary 23, 2023 | finance.yahoo.comLantheus Holdings (LNTH) Q4 Earnings and Revenues Surpass EstimatesFebruary 23, 2023 | finance.yahoo.comLantheus Shares Jump On Upbeat 2023 Guidance, Q4 Earnings Surpass ExpectationsFebruary 17, 2023 | finance.yahoo.comDo Its Financials Have Any Role To Play In Driving Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Stock Up Recently?February 16, 2023 | finance.yahoo.comLantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA LevelsFebruary 9, 2023 | finance.yahoo.comLantheus to Host Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast on February 23, 2023, at 8:00 a.m. Eastern TimeFebruary 8, 2023 | finance.yahoo.comLantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers SymposiumFebruary 6, 2023 | finance.yahoo.comLantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s DiseaseFebruary 2, 2023 | finance.yahoo.comInvestors’ Concerns Hit Lantheus Holdings (LNTH) Stock in Q4See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address LNTH Company Calendar Last Earnings2/23/2023Today3/22/2023Next Earnings (Estimated)5/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LNTH CUSIPN/A CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees612Year FoundedN/APrice Target and Rating Average Stock Price Forecast$107.33 High Stock Price Forecast$120.00 Low Stock Price Forecast$91.00 Forecasted Upside/Downside+29.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.34 Trailing P/E Ratio243.71 Forward P/E Ratio18.58 P/E GrowthN/ANet Income$28.07 million Net Margins3.00% Pretax Margin2.86% Return on Equity51.60% Return on Assets25.64% Debt Debt-to-Equity Ratio1.25 Current Ratio2.74 Quick Ratio2.59 Sales & Book Value Annual Sales$935.06 million Price / Sales5.99 Cash Flow$5.04 per share Price / Cash Flow16.45 Book Value$6.50 per share Price / Book12.75Miscellaneous Outstanding Shares67,540,000Free Float66,459,000Market Cap$5.60 billion OptionableOptionable Beta0.64 Key ExecutivesMary Anne HeinoPresident, Chief Executive Officer & DirectorPaul BlanchfieldChief Operating OfficerRobert J. MarshallChief Financial Officer & TreasurerSimon RobinsonSenior VP-Research & Pharmaceutical DevelopmentIryna TeslenkoVice President-Clinical DevelopmentKey CompetitorsQuidelOrthoNASDAQ:QDELNeogenNASDAQ:NEOGIntellia TherapeuticsNASDAQ:NTLACelldex TherapeuticsNASDAQ:CLDXMyriad GeneticsNASDAQ:MYGNView All CompetitorsInsiders & InstitutionsRobert J Jr. MarshallSold 5,000 sharesTotal: $357,900.00 ($71.58/share)Andrea SabensSold 386 sharesTotal: $27,629.88 ($71.58/share)Mary Anne HeinoSold 10,064 sharesTotal: $751,780.80 ($74.70/share)Robert J Jr. MarshallSold 20,587 sharesTotal: $1.49 M ($72.56/share)Etienne MontagutSold 14,179 sharesTotal: $1.03 M ($72.56/share)View All Insider TransactionsView All Institutional Transactions LNTH Stock - Frequently Asked Questions Should I buy or sell Lantheus stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LNTH shares. View LNTH analyst ratings or view top-rated stocks. What is Lantheus' stock price forecast for 2023? 6 Wall Street analysts have issued 12-month price objectives for Lantheus' shares. Their LNTH share price forecasts range from $91.00 to $120.00. On average, they expect the company's share price to reach $107.33 in the next year. This suggests a possible upside of 29.5% from the stock's current price. View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts. How have LNTH shares performed in 2023? Lantheus' stock was trading at $50.96 on January 1st, 2023. Since then, LNTH stock has increased by 62.6% and is now trading at $82.86. View the best growth stocks for 2023 here. Are investors shorting Lantheus? Lantheus saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 3,720,000 shares, an increase of 32.9% from the February 13th total of 2,800,000 shares. Based on an average trading volume of 1,130,000 shares, the short-interest ratio is currently 3.3 days. Approximately 5.6% of the company's shares are short sold. View Lantheus' Short Interest. When is Lantheus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. View our LNTH earnings forecast. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) issued its earnings results on Thursday, February, 23rd. The medical equipment provider reported $1.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.87 by $0.41. The medical equipment provider had revenue of $263.17 million for the quarter, compared to the consensus estimate of $244.61 million. Lantheus had a net margin of 3.00% and a trailing twelve-month return on equity of 51.60%. What ETFs hold Lantheus' stock? ETFs with the largest weight of Lantheus (NASDAQ:LNTH) stock in their portfolio include Harbor Health Care ETF (MEDI), AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ), SPDR S&P Health Care Equipment ETF (XHE), Inspire Fidelis Multi Factor ETF (FDLS), Invesco S&P MidCap 400 Pure Growth ETF (RFG), AdvisorShares Alpha DNA Equity Sentiment ETF (SENT), Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC) and First Trust Active Factor Small Cap ETF (AFSM). What guidance has Lantheus issued on next quarter's earnings? Lantheus issued an update on its first quarter 2023 earnings guidance on Thursday, February, 23rd. The company provided EPS guidance of $1.28-$1.32 for the period, compared to the consensus EPS estimate of $1.06. The company issued revenue guidance of $280.00 million-$285.00 million, compared to the consensus revenue estimate of $253.59 million. What is Mary Anne Heino's approval rating as Lantheus' CEO? 4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO). When did Lantheus IPO? (LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager. What is Lantheus' stock symbol? Lantheus trades on the NASDAQ under the ticker symbol "LNTH." Who are Lantheus' major shareholders? Lantheus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (4.64%), Dimensional Fund Advisors LP (2.10%), Geode Capital Management LLC (1.89%), Silvercrest Asset Management Group LLC (1.63%), T. Rowe Price Investment Management Inc. (1.54%) and Price T Rowe Associates Inc. MD (1.51%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lantheus' stock price today? One share of LNTH stock can currently be purchased for approximately $82.86. How much money does Lantheus make? Lantheus (NASDAQ:LNTH) has a market capitalization of $5.60 billion and generates $935.06 million in revenue each year. The medical equipment provider earns $28.07 million in net income (profit) each year or $0.34 on an earnings per share basis. How many employees does Lantheus have? The company employs 612 workers across the globe. How can I contact Lantheus? Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for the company is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at ir@lantheus.com, or via fax at 978-671-8860. This page (NASDAQ:LNTH) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.